Anthony Hunt Sells 22,191 Shares of Repligen Co. (NASDAQ:RGEN) Stock

Repligen Co. (NASDAQ:RGEN) Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Anthony Hunt also recently made the following trade(s):

• On Friday, June 14th, Anthony Hunt acquired 2,000 shares of Repligen stock. The shares were purchased at an average cost of $124.08 per share, with a total value of $248,160.00.

Repligen Stock Down 1.4 %

RGEN opened at $139.99 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a one year low of $110.45 and a one year high of $211.13. The firm has a market capitalization of $7.84 billion, a P/E ratio of 559.98, a price-to-earnings-growth ratio of 4.24 and a beta of 0.94. The company has a fifty day moving average price of $145.43 and a 200-day moving average price of $157.36.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to analysts’ expectations of $154.11 million. During the same period in the previous year, the business earned $0.53 earnings per share. The firm’s revenue was down 3.2% on a year-over-year basis. Equities research analysts expect that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RGEN. Deutsche Bank Aktiengesellschaft raised Repligen from a “hold” rating to a “buy” rating and dropped their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Wells Fargo & Company started coverage on shares of Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. UBS Group cut their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a report on Wednesday, July 31st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $190.00 target price on shares of Repligen in a report on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $188.38.

Institutional Investors Weigh In On Repligen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Truist Financial Corp raised its position in shares of Repligen by 14.5% during the 4th quarter. Truist Financial Corp now owns 4,250 shares of the biotechnology company’s stock valued at $764,000 after buying an additional 538 shares in the last quarter. Victory Capital Management Inc. raised its position in Repligen by 9.5% during the fourth quarter. Victory Capital Management Inc. now owns 21,271 shares of the biotechnology company’s stock valued at $3,825,000 after purchasing an additional 1,851 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Repligen by 4.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 342,452 shares of the biotechnology company’s stock worth $61,573,000 after purchasing an additional 15,785 shares during the last quarter. Principal Securities Inc. purchased a new position in shares of Repligen in the 4th quarter worth about $48,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Repligen by 5.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 301,968 shares of the biotechnology company’s stock valued at $54,306,000 after purchasing an additional 16,430 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.